HK2 and urinary bladder carcinoma: Similarly, in bladder cancer, LC-MS/MS revealed that HK2-mediated glycolytic flux drives cisplatin resistance, prompting the development of the HK2 inhibitor, which synergized with sorafenib to inhibit tumor growth (Gong et al., 2025; DeWaal et al., 2018).